COVID-19: Pfizer Vaccine May Be Available To Americans By Year End
Pfizer’s vaccine candidate is currently undergoing Phase-3 clinical trials in the US.
American pharmaceutical company Pfizer has said that it is working towards making its COVID-19 vaccine available to the American market by the end of this year.
“We (have) already started manufacturing, and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout… we will be ready.”Albert Bourla, CEO, Pfizer
Pfizer’s vaccine candidate is one of the frontrunners in the race to produce a coronavirus vaccine, and is currently undergoing Phase-3 clinical trials in the US. The vaccine is being jointly developed with the German company BioNTech.
The Phase-3 trials for the vaccine candidate are expected to continue well beyond October, but the company is expectant that early data would present adequate evidence to ascertain if the vaccine works. Bourla added that there was a 60 per cent chance that by October, the company would be able to determine the efficacy of its vaccine.
“Of course that does not mean that it works, that only means that we will know if it works.”Albert Bourla, CEO, Pfizer
Pfizer also stated recently that it plans to expand its Phase-3 trials to include more participants from diverse population groups. Initially, about 30,000 volunteers were to be enrolled for the vaccine trials. Now, an additional 14,000 volunteers are expected to participate.
(Make sure you don't miss fresh news updates from us. Click here to stay updated)
Subscribe To Our Daily Newsletter Now.